RxDoctor Payments Data

Basil Abdo, MD

Family Medicine · Redford, MINPI 1730121443

Payments from drug & device makers

$3,823in general payments, 2019–2025

Across 227 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$756
  • Novo Nordisk$651
  • Lilly USA, LLC$521
  • Pfizer$445
  • AstraZeneca$402
  • Boehringer Ingelheim$285
  • plus $764 from 14 others

What the payments were for

  • Food & beverage$3,823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,823 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$65,446
Medicare patients
144
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$135,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,313
JanuviaSitagliptin Phosphate22$31,868
TradjentaLinagliptin22$26,198
EliquisApixaban20$13,486
RybelsusSemaglutide11$10,320
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,219
Atorvastatin Calcium451$4,891
Metoprolol Succinate290$4,241
SymbicortBudesonide/Formoterol Fumarate14$4,050
Omeprazole306$4,012
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,513
Losartan Potassium225$3,074
Levothyroxine Sodium229$2,852
FenofibrateFenofibrate Nanocrystallized95$2,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$285$161,711140 claims
GSKTrelegy Ellipta, Arnuity Ellipta$756$35,95155 claims
MerckJanuvia$88$31,86822 claims
PfizerEliquis, Dilantin$445$15,18132 claims
Novo NordiskRybelsus$651$10,32011 claims
AstraZenecaSymbicort$402$4,05014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Redford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →